Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357239 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
NCT01357239 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 139 participants.
The verdict
NCT01357239, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
Study Summary
This Phase IIb study is designed to assess whether 3 doses of AFQ056 are safe and effective in treating the behavioral symptoms of Fragile X Syndrome.
Interventions
- DRUG Placebo
- DRUG AFQ056
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01357239
The ClinicalTrials.gov registry entry for NCT01357239 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01357239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01357239 about?
NCT01357239 is a clinical study titled "Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome". This Phase IIb study is designed to assess whether 3 doses of AFQ056 are safe and effective in treating the behavioral symptoms of Fragile X Syndrome.
What is the current status of trial NCT01357239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2011-05. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01357239?
The interventions under investigation include: Placebo (DRUG), AFQ056 (DRUG).
Who is sponsoring clinical trial NCT01357239?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.